文献速递脑血管病

左心耳封堵对比口服抗凝预防房颤卒中的更新荟萃分析

Updated Meta-Analysis of Left Atrial Appendage Closure Versus Oral Anticoagulation to Prevent Stroke in Atrial Fibrillation
RSS 订阅 · Stroke

该系统综述与荟萃分析纳入6项随机对照试验、7028例非瓣膜性房颤患者,比较经皮左心耳封堵与口服抗凝。总体上,卒中发生率两组相似,但左心耳封堵组缺血性卒中更常见,非操作相关出血更低。结论认为左心耳封堵更适合用于降低标准至中度出血风险且符合抗凝条件患者的非操作相关出血,而非作为口服抗凝的卒中等效替代。

要点

  • 左心耳封堵后缺血性卒中风险可能高于口服抗凝,需谨慎解读。
  • 左心耳封堵主要优势是减少非操作相关出血,但高出血风险患者未获益。
  • 不宜将左心耳封堵视为口服抗凝在卒中预防上的等效替代。

核心结论

  • 左心耳封堵最合适的定位是在符合抗凝条件且出血风险为标准至中度的患者中降低非操作相关出血,而非作为口服抗凝在卒中预防上的等效替代。

研究设计与样本

  • 系统综述与荟萃分析检索PubMed、Scopus和Embase自建库至2026年4月15日,纳入比较经皮左心耳封堵与口服抗凝的随机对照试验。
  • 共纳入6项随机对照试验,时间跨度2014至2026年,涉及北美、欧洲和亚洲358个中心,共7028例非瓣膜性房颤患者。
  • 使用Cochrane偏倚风险2工具评估偏倚风险,以随机效应模型合并累积发生率结局为比值比,并提供预测区间、预设亚组和试验序贯分析。

主要发现

  • 总体卒中率两组相似,比值比1.10(95%CI 0.78–1.56)。
  • 左心耳封堵组缺血性卒中更常见,比值比1.41(95%CI 1.07–1.86),但未达到所需信息量。
  • 左心耳封堵组非操作相关出血更低,比值比0.58(95%CI 0.35–0.96),是唯一达到充分信息量的结局。
  • 非操作相关出血的降低见于标准风险及消融后患者,高出血风险患者未见降低。

关键数值与推荐

  • 2项试验比较左心耳封堵与华法林,4项试验与直接口服抗凝药比较。
  • 人群主要为符合抗凝条件且既往卒中患病率较低的患者,另有2项高出血风险试验和1项消融后试验。

临床怎么用

  • 对符合抗凝条件且出血风险为标准至中度的房颤患者,可考虑左心耳封堵以降低非操作相关出血。
  • 不应常规将左心耳封堵作为口服抗凝在卒中预防上的等效替代方案。

局限性

  • 缺血性卒中终点未达到试验序贯分析所需的充分信息量。
  • 非操作相关出血的降低仅限于标准风险和消融后患者,高出血风险患者未见获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stroke, Volume 57, Issue 11, Page 3233-3244, November 1, 2026. BACKGROUND:Ninety percent of left atrial thrombi in nonvalvular atrial fibrillation arise in the left atrial appendage, which can be occluded percutaneously (left atrial appendage closure [LAAC]). Two 2026 trials (CHAMPION-AF [Watchman Flx Versus Non-Vitamin K Antagonist Oral Anticoagulant for Embolic Protection in the Management of Patients With Non-Valvular Atrial Fibrillation] and CLOSURE-AF [Left Atrial Appendage Closure in Patients With Atrial Fibrillation Compared to Medical Therapy]) more than doubled the available randomized evidence comparing LAAC with oral anticoagulation. We evaluated pooled effects of LAAC on stroke, bleeding, and mortality by bleeding risk, anticoagulation eligibility, and comparator.METHODS:In this systematic review and meta-analysis, we searched PubMed, Scopus, and Embase from inception to April 15, 2026, for randomized controlled trials comparing percutaneous LAAC with oral anticoagulation in nonvalvular atrial fibrillation. Risk of bias was assessed with the Cochrane Risk of Bias 2 tool. Cumulative-incidence outcomes were pooled as odds ratios using random-effects models, with prediction intervals, prespecified subgroups, and trial sequential analysis.RESULTS:Six randomized controlled trials (2014–2026; 358 sites in North America, Europe, and Asia; 7028 patients) compared LAAC with warfarin (2 trials) or a direct oral anticoagulant (4 trials); populations were predominantly anticoagulation-eligible with low prior-stroke prevalence, plus 2 high-bleeding-risk and 1 postablation trial. Overall stroke rates were similar between arms (odds ratio, 1.10 [95% CI, 0.78–1.56]). Ischemic stroke was more frequent with LAAC (odds ratio, 1.41 [95% CI, 1.07–1.86]) but did not reach the required information size. Nonprocedural bleeding was lower with LAAC (odds ratio, 0.58 [95% CI, 0.35–0.96]), the only outcome reaching a sufficient information size, in standard-risk and postablation but not high-bleeding-risk patients.CONCLUSIONS:LAAC is best positioned to reduce nonprocedural bleeding in anticoagulation-eligible patients at standard-to-moderate bleeding risk, rather than as a stroke-equivalent substitute for oral anticoagulation.REGISTRATION:URL:https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD420261370546.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Stroke:Updated Meta-Analysis of Left Atrial Appendage Closure Versus Oral Anticoagulation to Prevent Stroke in Atrial Fibrillation

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。